Background: Cancer stem cells (CSCs) are key contributors to treatment failure in clear cell renal cell carcinoma (ccRCC). Our prior single-cell RNA-seq analyses identified CSCs as the predominant source of SPP1, which may maintain stemness and promote progression via JAK1/STAT3 signaling, with POU5F1 as a putative upstream regulator. However, these SPP1-centered roles and their upstream/downstream mechanisms remain to be systematically validated. Methods: We integrated bioinformatics analysis with experimental validation using functional assays (proliferation, migration, tumorsphere formation), molecular mechanism studies (ChIP, Co-IP, dual-luciferase assays), and in vivo xenograft models to investigate the roles and mechanisms of SPP1. Results: In 30 paired tissues, POU5F1 and SPP1 were upregulated in ccRCC, and concurrent high expression in The Cancer Genome Atlas predicted poorer overall survival. In 786-O/769-P cells, loss- and gain-of-function experiments showed that either gene modulated proliferation, EdU incorporation, migration, and tumorsphere formation. SPP1 silencing reduced pJAK1/pSTAT3, whereas STAT3 blockade partially reversed SPP1-induced phenotypes. POU5F1 occupied the SPP1 promoter and increased promoter-driven transcription, leading to higher SPP1 expression and secretion; SPP1 knockdown attenuated POU5F1-overexpression effects. In xenografts, lowering POU5F1 or SPP1 decreased tumor growth, Ki-67, stem-like/EMT markers, and JAK1/STAT3 activity. Conclusions: Our findings support a POU5F1-SPP1- JAK1/STAT3 axis that sustains stem-like traits and malignant behavior in ccRCC. Targeting this axis may concurrently suppress bulk tumor cells and CSCs compartments, providing a biomarker-guided, dual-hit therapeutic rationale.